Further Information:
The Health Products Regulatory Authority has been notified of a shortage of the following products:
- Clexane 2,000 IU (20mg)/0.2 mL Solution for Injection in Pre Filled Syringes - PA0540/097/004
- Clexane 6,000 IU (60mg)/0.6 mL Solution for Injection in Pre Filled Syringes - PA0540/097/006
- Clexane 8,000 IU (80mg)/0.8 mL Solution for Injection in Pre Filled Syringes - PA0540/097/007
- Clexane 10,000 IU (100mg)/1ml Solution for Injection in Pre Filled Syringes - PA0540/097/001
- Claforan Powder for Solution for Injection 1g - PA0540/037/003
- Combodart 0.5mg/ 0.4mg Hard Capsules - PA1077/118/001
- Dopamine Hydrochloride 40mg/ml Sterile Concentrate - PA0822/202/001
- Gerax 250mcg Tablets- PA1445/024/001
- Ondansetron 2mg/ml Solution for Injection (2ml presentation) - PA1122/004/001
- Relpax 40mg Film Coated Tablets - PA23055/002/002
The following shortages have been resolved and supply has resumed to the Irish market:
- Abstral 400mcg Sublingual Tablets - PA2288/004/005
- Abstral 800mcg Sublingual Tablets - PA2288/004/007
- Amitriptyline 25mg Film Coated Tablets - PA0126/041/001
- Canesten HC 1% w/w + 1% w/w Cream - PA1410/040/002
- Fexofenadine Hydrochloride 120mg Film Coated Tablets - PA22871/004/002
- Fexofenadine Hydrochloride 180 mg Film Coated Tablets - PA22871/004/003
- Hytrin 10mg Tablets - PA1142/005/004
- Innohep 8,000 IU in 0.4 ml, Solution for Injection - PA0046/060/012
- Innohep 10,000 IU/ml Solution for Injection - PA0046/060/002
- Innohep 10,000 IU in 0.5 ml, Solution for Injection - PA0046/060/010
- Odrik 2mg Hard Capsule - PA2010/005/003
- OxyNorm Dispersa 10mg Orodispersible Tablets - PA1688/006/008
- OxyNorm Dispersa 20mg Orodispersible Tablets - PA1688/006/009
- Paralief 500mg Tablets (24 pack) - PA0126/020/001
- Temodal 180mg Capsules - EU/1/98/096/019
Please see the shortages section of the HPRA website for further information.
The HPRA will be sending weekly updates concerning medicinal product shortages. However, the above webpage will be updated as new information is provided to the HPRA.